Kura Oncology
KURA
179 hedge funds and large institutions have $1.61B invested in Kura Oncology in 2024 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 63 increasing their positions, 54 reducing their positions, and 16 closing their positions.
31% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 16
27% more call options, than puts
Call options by funds: $853K | Put options by funds: $671K
17% more repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 54
3% more funds holding
Funds holding: 174 → 179 (+5)
1.82% more ownership
Funds ownership: 105.66% → 107.48% (+1.8%)
3% less capital invested
Capital invested by funds: $1.66B → $1.61B (-$50.3M)
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$32M |
| 2 |
SCM
Suvretta Capital Management
New York
|
+$11.8M |
| 3 |
Millennium Management
New York
|
+$10.2M |
| 4 |
Walleye Capital
New York
|
+$10.1M |
| 5 |
AC
Armistice Capital
New York
|
+$6.24M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AG
Artal Group
Luxembourg
|
-$37.5M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
-$14.4M |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$13.8M |
| 4 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$10.7M |
| 5 |
State Street
Boston,
Massachusetts
|
-$4.37M |
KURA Hedge Fund Activity: Q3 2024 in Review
179 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in Kura Oncology (KURA) for Q3 2024, worth a combined $1.61B — down 3% from $1.66B a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new KURA positions and 16 closed out — a net gain of 5 holders — while 63 added to existing stakes and 54 trimmed.
The largest buyer was Deep Track Capital, adding an estimated $32M. The largest seller was Artal Group, exiting entirely with an estimated $37.5M sold.
- 179 institutional investors held Kura Oncology (KURA) as of Q3 2024, up from 174 in Q2 2024.
- Funds reported $1.61B of Kura Oncology stock for Q3 2024, down 3% quarter-over-quarter.
- 21 funds opened new Kura Oncology positions in Q3 2024 and 16 closed out, a net change of +5 holders.
- The largest Kura Oncology buyer in Q3 2024 was Deep Track Capital, an estimated $32M added.
- The largest Kura Oncology seller in Q3 2024 was Artal Group, an estimated $37.5M sold.
Based on aggregated 13F filings for Q3 2024.